Researchers repurposed CRISPR/Cas9 epigenetic editing technology in hopes of characterizing transcriptional changes and effects in different tumor settings.

Researchers discovered an enzyme, originally known to regulate the TGF-β, has a previously unreported role in HIF-1α regulation.

In a trending paper published by Oncotarget, researchers developed a divergent strategy to treat non-small cell lung cancer (NSCLC).